Takeda Pharmaceutical (4502.T) stock price, revenue, and financials

Takeda Pharmaceutical market cap is ¥5.1 t, and annual revenue was ¥3.29 t in FY 2020

¥5.1 T

4502.T Mkt cap, 10-Nov-2021

¥1.6 T

Takeda Pharmaceutical Revenue H1, 2021
Takeda Pharmaceutical Gross profit (H1, 2021)1.1 T
Takeda Pharmaceutical Gross profit margin (H1, 2021), %69.3%
Takeda Pharmaceutical Net income (H1, 2021)86.6 B
Takeda Pharmaceutical EBIT (H1, 2021)215.6 B
Takeda Pharmaceutical Cash, 30-Sept-2020630.9 B
Takeda Pharmaceutical EV9.4 T
Get notified regarding key financial metrics and revenue changes at Takeda PharmaceuticalLearn more
Banner background

Takeda Pharmaceutical Revenue

Takeda Pharmaceutical revenue was ¥3.29 t in FY, 2020 which is a 56.9% year over year increase from the previous period.

Embed Graph

Takeda Pharmaceutical Revenue Breakdown

Embed Graph

Takeda Pharmaceutical revenue breakdown by business segment: 13.3% from Neuroscience, 12.8% from Oncology, 12.0% from PDT Immunology, 10.2% from Rare Hematology, 5.2% from Rare Metabolic, 21.2% from Gastroenterology and 25.4% from Other

Takeda Pharmaceutical revenue breakdown by geographic segment: 5.0% from Asia (excluding Japan), 19.6% from Europe and Canada, 48.5% from United States, 18.0% from Japan and 8.9% from Other

Takeda Pharmaceutical Income Statement

Annual

JPYFY, 2018FY, 2019FY, 2020

Revenue

1.8t2.1t3.3t

Revenue growth, %

18%57%

Cost of goods sold

495.9b659.7b1.1t

Gross profit

1.3t1.4t2.2t

Gross profit Margin, %

72%69%67%

R&D expense

325.4b368.3b492.4b

General and administrative expense

628.1b717.6b964.7b

Operating expense total

1.2t1.2t2.1t

Depreciation and amortization

122.1b203.4b455.4b

EBIT

241.8b205.0b100.4b

EBIT margin, %

14%10%3%

Interest expense

10.0b48.2b149.0b

Interest income

3.3b6.6b11.2b

Pre tax profit

217.2b94.9b(60.8b)

Income tax expense

30.5b(14.1b)(105.0b)

Net Income

186.7b109.0b44.3b

EPS

237.6112.928.3

Half Year

JPYH1, 2019H1, 2020H1, 2021

Revenue

880.6b1.7t1.6t

Cost of goods sold

231.3b572.3b487.7b

Gross profit

649.3b1.1t1.1t

Gross profit Margin, %

74%66%69%

R&D expense

151.4b230.4b225.0b

General and administrative expense

293.8b462.5b418.6b

Operating expense total

477.3b1.0t895.0b

Depreciation and amortization

48.3b273.7b208.1b

EBIT

172.0b50.3b215.6b

EBIT margin, %

20%3%14%

Pre tax profit

160.8b(27.6b)125.6b

Income tax expense

34.3b(60.8b)39.0b

Net Income

126.5b33.3b86.6b

EPS

160.921.355.1

Takeda Pharmaceutical Balance Sheet

Annual

JPYFY, 2018FY, 2019FY, 2020

Cash

294.5b702.1b637.6b

Accounts Receivable

369.7b661.0b715.2b

Inventories

212.9b986.7b759.6b

Current Assets

1.1t3.1t2.5t

PP&E

536.8b1.3t1.4t

Goodwill

1.0t4.2t4.0t

Total Assets

4.1t13.9t12.8t

Accounts Payable

133.7b212.3b211.6b

Short-term debt

18.0m984.9b586.8b

Current Liabilities

737.5b2.5t2.2t

Long-term debt

985.6b4.8t4.5t

Non-Current Liabilities

1.4t6.2t5.9t

Total Debt

985.7b5.8t5.1t

Total Liabilities

2.1t8.7t8.1t

Common Stock

77.9b1.6t1.7t

Additional Paid-in Capital

90.7b1.7t1.7t

Retained Earnings

1.6t1.6t1.4t

Total Equity

2.0t5.2t4.7t

Debt to Equity Ratio

0.5 x1.1 x1.1 x

Debt to Assets Ratio

0.2 x0.4 x0.4 x

Financial Leverage

2 x2.7 x2.7 x

Takeda Pharmaceutical Cash Flow

Annual

JPYFY, 2018FY, 2019FY, 2020

Net Income

186.7b109.0b44.3b

Depreciation and Amortization

182.1b272.4b583.6b

Accounts Receivable

(647.0m)(13.4b)(34.8b)

Inventories

13.7b58.7b137.5b

Accounts Payable

6.9b(16.4b)(29.9b)

Cash From Operating Activities

377.9b328.5b669.8b

Purchases of PP&E

(67.0b)(77.7b)(127.1b)

Cash From Investing Activities

(93.3b)(2.8t)292.1b

Short-term Borrowings

(403.9b)367.3b(351.2b)

Long-term Borrowings

(82.7b)(1.7b)(731.1b)

Dividends Paid

(141.9b)(143.0b)(282.6b)

Cash From Financing Activities

(326.2b)2.9t(1.0t)

Net Change in Cash

(41.7b)439.0b(43.3b)

Interest Paid

8.4b34.9b127.2b

Income Taxes Paid

54.9b51.5b234.6b

Takeda Pharmaceutical Ratios

JPYFY, 2018

EV/EBIT

3 x

EV/CFO

1.9 x

Revenue/Employee

65.0m

Debt/Equity

0.5 x

Debt/Assets

0.2 x

Financial Leverage

2 x

P/E Ratio

0.1

Takeda Pharmaceutical Operating Metrics

Oct, 2018Feb, 2019May, 2019Jul, 2019Oct, 2019Feb, 2020May, 2020Jul, 2020Oct, 2020

Filed Trials Products (Gastro-Enterology)

125655335

Filed Trials Products (Neuroscience)

211111

Filed Trials Products (Oncology)

215669868

Filed Trials Products (Plasma-Derived Therapies)

1

Filed Trials Products (Rare Genetic & Hematology)

11122111

Phase I Trials Products (Oncology)

5311

Phase I Trials Products (Rare Diseases)

111

Phase I/II Trials Products (Gastro-Enterology)

1111

Phase I/II Trials Products (Oncology)

5443

Phase I/II Trials Products (Rare Genetic & Hematology)

1111

Phase II Trials Products (Gastro-Enterology)

2211

Phase II Trials Products (Oncology)

79778

Phase III Trials Products (Gastro-Enterology)

799655675

Phase III Trials Products (Neuroscience)

121111

Phase III Trials Products (Oncology)

8910777765

Phase III Trials Products (Plasma-Derived Therapies)

53333333

Phase III Trials Products (Rare Genetic & Hematology)

44446667

Takeda Pharmaceutical Human Capital

FY, 2020FY, 2019FY, 2018
Female, percent25%23.5%
Male (Managers), percent30%62%31.5%
Male, percent25%26.5%
Female (Managers), percent20%38%18.5%

Takeda Pharmaceutical Employee Rating

3.92733 votes
Culture & Values
3.8
Work/Life Balance
3.7
Senior Management
3.3
Salary & Benefits
4
Career Opportunities
3.5
Source